Clinical Trial of Safety, Pharmacodynamics and Pharmacokinetic Characteristics of Multiple Subcutaneous Injections of LP-98 in Primary Treatment of HIV-infected Patients
Latest Information Update: 30 Sep 2024
At a glance
- Drugs LP 98 (Primary)
- Indications HIV infections
- Focus Adverse reactions
- Sponsors Shanxi Kangbao Biological Product
Most Recent Events
- 04 Sep 2024 Status changed from not yet recruiting to recruiting.
- 23 Aug 2024 New trial record